Navigation Links
Novel Diabetes Drug Discovery Has Potential to Reverse Disease
Date:1/27/2009

WYNNEWOOD, Pa., Jan. 27 /PRNewswire/ -- A study released today in Endocrine Practice (2008;14:1075), the leading peer-reviewed journal for practicing endocrinologists in the US and 65 countries, reports a ground breaking discovery with the potential to reverse type 1 and 2 diabetes. Scientists at CureDM, Inc. have identified a 14- amino acid human peptide, Human proIslet Peptide (HIP), consisting of the bioactive region in the human REG3a gene responsible for regenerating pancreatic islets, a process also known as islet neogenesis. "Utilizing an innovative and proprietary approach to evaluate the human genome and proteome from a physiologic perspective, we were able to identify a highly conserved bioactive gene product that triggers islet neogenesis. Restoring functional islets as a therapeutic approach is fundamental to curing the underlying disease," said Claresa S. Levetan, MD, FACE, Chief Medical Officer and Founder of CureDM, Inc.

CureDM has produced, stabilized and characterized this unique peptide in a variety of preclinical studies. In these studies, researchers have demonstrated that HIP stimulates insulin secretion in human pancreatic ductal tissue devoid of islets. HIP was also shown to stimulate new islet formation with a 3-fold increase in islet numbers in validated diabetic animal models compared to placebo, effectively reversing the disease in such animals. "Having demonstrated the preclinical proof of concept of this promising and novel therapeutic approach, we look forward to obtain regulatory approval and initiation of clinical testing of HIP in 2009," said H. Joseph Reiser Ph.D., Chief Executive Officer of CureDM.

The incidence of diabetes continues to grow at a double-digit rate worldwide with nearly 300 million patients estimated by 2030. At the time of diagnosis, islet mass is often reduced by 80% in type 1 patients and 50% in type 2 patients, supporting the importance of islet restoration as a therapeutic approach. Pancreatic islets contain four primary cell types and are responsible for producing insulin, amylin, glucagon and other hormones critical to maintaining normal glucose regulation. Current diabetes therapies, including insulin, help to control the disease but do not restore new islets. HIP addresses the underlying mechanism of the pathology of diabetes and represents a potentially curative approach to both, type 1 and 2 diabetes. If successful in human clinical trials, HIP-induced restoration of islet function has the potential to become a first-line treatment approach for diabetes and pre- diabetes.

About HIP

Human proIslet Peptide (HIP) is a 14-amino acid, stabilized human peptide that stimulates the signal pathways that induce new islet formation in the pancreas, without the use of stem cells. HIP creates new insulin-producing beta cells by generating new islets that contain alpha, beta, gamma and delta cells, all of which are necessary to regulate glucose metabolism. The core patent for the HIP technology was issued in July 2008.

About CureDM

CureDM is a Biotherapeutics company focusing on Diseases of Metabolism. CureDM has developed a proprietary platform technology using genomics and proteomics to identify bioactive components of gene products that are fundamental to address unmet medical needs. HIP is the first product derived from this process with other pipeline compounds under development. CureDM, Inc. is located in the Lankenau Institute for Medical Research at the Lankenau Hospital campus in Wynnewood, PA. For further information visit www.curedm.com

About Endocrine Practice

Endocrine Practice is the peer-reviewed journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists read by more than 6000 endocrinologists. The content of Endocrine Practice is covered by Index Medicus and EMBASE. For further information visit www.aace.com


'/>"/>
SOURCE CureDM, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. IDRI Collaborates with the Brazilian Butantan Institute To Develop Novel Vaccines Against Leishmaniasis
2. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
3. Data Published in Nature Cell Biology Reveal Novel Function of Drug Target EpCAM in Cancer Cell Signalling
4. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
5. Parion Sciences Receives NIH Biodefense Grant to Study Novel Methods for Mitigating Radiation-Induced Lung Injury
6. Medivation Presents New Data on Dimebons Novel Mechanism of Action
7. Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting
8. Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for ZP1846, a Novel GLP-2 Agonist
9. ScinoPharm Granted US Patent for Novel Crystal Forms
10. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
11. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... Newly created 4Sight Medical Solutions ... the healthcare market. The company's primary focus is on new product introductions, to ... that are necessary to help companies efficiently bring their products to market. , ...
(Date:6/24/2016)... TOKYO , June 24, 2016  Regular discussions on ... to take place between the two entities said Poloz. ... in Ottawa , he pointed to the ... and the federal government. ... Poloz said, "Both institutions have common economic goals, why not ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
Breaking Biology News(10 mins):